View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Tina B. Stacy, PharmD, BCOP, CHCP
(404) 425-4474
tstacy@clinicaloptions.com
www.clinicaloptions.com
EASL 2019 downloadable slideset: Phase II efficacy and safety results of emricasan, an oral caspase inhibitor, in NASH cirrhosis and severe portal HTN as reported by Clinical Care Options (CCO)
Planned Month 18 interim analysis of phase III REGENERATE study of obeticholic acid vs placebo for NASH from EASL 2019, reported by CCO
Kenneth Cusi, MD, FACP, FACE, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.
Kenneth Cusi, MD, FACP, FACE
Released: March 29, 2019
Stephen A. Harrison, MD, COL (Ret.), FAASLD, explains how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: March 29, 2019
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.